Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begun dosing in its IND-enabling study of proprietary time-released, topical formulation of ketamine SP-26 designed to treat fibromyalgia. 

This safety evaluation trial will be conducted by Experimur, a Frontage Company, and intends to evaluate the tolerability of SP-26 to establish a maximum dose in the treatment of this chronic medical condition causing widespread musculoskeletal pain as well as memory issues, sleep difficulties and fatigue.

Silo Pharma’s CEO Eric Weisblum

Full story available on Benzinga.com